# Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

> **NCT03376516** · PHASE3 · COMPLETED · sponsor: **Octapharma** · enrollment: 11 (actual)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** Wilate

## Key facts

- **NCT ID:** NCT03376516
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-22
- **Primary completion:** 2018-11-03
- **Final completion:** 2018-11-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03376516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03376516, "Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03376516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*